"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02163538","Articulating Enseal Versus Ligasure Energy Devices",,"Completed","Has Results","Task Performance","Device: articulating Enseal|Device: Ligasure device","Raw Task Load Index (TLX) Score Assigned by Surgeons|Intra- and Post-operative Complications|Estimated Blood Loss|Need for Second Energy Device Intra-operatively|Time From Port Placement to Bilateral Uterine Artery Ligation and Hemostatsis.|Time Required to Complete Procedure","University of Louisville|Ethicon Endo-Surgery","Female","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","142","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","Energy Devices-UL","July 2014","April 2016","April 2016","June 13, 2014","January 17, 2018","February 13, 2018","University of Louisville Health Care Outpatient Center, Louisville, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02163538"
2,"NCT01303159","Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer",,"Terminated","Has Results","Cholangiocarcinoma|Pancreatic Cancer","Device: Endoscopic bipolar radiofrequency probe (ENDOHPB)","Change From Baseline in Bile Duct Stricture Diameter|Number of Participants With Adverse Events","Weill Medical College of Cornell University|EMcision Limited","All","18 Years and older   (Adult, Older Adult)","Not Applicable","29","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1107011793","March 2010","January 13, 2014","January 13, 2014","February 24, 2011","May 23, 2017","May 23, 2017","Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01303159"
3,"NCT01182285","A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin",,"Completed","Has Results","Thyroid Neoplasm","Drug: Valproic Acid|Drug: Liothyronine Sodium","RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment|Number of Participants With Adverse Events|Best Overall Response|NIS (Na/I-symporter) Expression","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","13","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100041|10-C-0041","September 24, 2010","September 28, 2015","April 28, 2016","August 16, 2010","December 14, 2016","May 16, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT01182285/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT01182285"
4,"NCT00571688","Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?","Consta","Completed","Has Results","Bipolar Disorder","Drug: Risperdal (risperidone) Consta|Drug: Treatment as usual","Number of Relapse-related Events Normalized to Unit Time","Vanderbilt University|Ortho-McNeil Janssen Scientific Affairs, LLC|Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","RIS-BIP-4005","November 2007","February 2009","February 2009","December 12, 2007","July 31, 2017","July 31, 2017","Mental Health Cooperative, Inc., Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00571688"
5,"NCT03259555","A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder",,"Completed","Has Results","Bipolar I Disorder|Manic Episode","Drug: Brexpiprazole|Drug: Placebo","Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3|Change From Baseline In Clinical Global Impression-Bipolar (CGI-BP) Severity Score In Mania At Week 3","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","322","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-201-00080","September 14, 2017","January 2, 2019","January 2, 2019","August 23, 2017","February 10, 2020","February 10, 2020","Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|ProScience Research Group, Culver City, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|NRC Research Institute, Orange, California, United States|Asclepes Research Centers, Panorama City, California, United States|Ci Trials, Riverside, California, United States|Sharp Vista Hospital, San Diego, California, United States|Galiz Research, Hialeah, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Florida Behavioral Medicine, Largo, Florida, United States|Optimus U Corporation, Miami, Florida, United States|Behavioral Clinical Research, Inc., North Miami, Florida, United States|Segal Trials, North Miami, Florida, United States|Radiant Research Inc., Atlanta, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|CBH Health, Gaithersburg, Maryland, United States|Advanced Clinical Research Center, LLC, Saint Louis, Missouri, United States|Richard H Weisler, MD, PA, and Associates, Raleigh, North Carolina, United States|SP Research PLLC, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|University of Texas at Austin, Austin, Texas, United States|Community Clinical Research, Inc., Austin, Texas, United States|Pillar Clinical Research, LLC, Garland, Texas, United States|Pillar Clinical Research, LLC, Richardson, Texas, United States|Mid Columbia Research, Richland, Washington, United States|Mental Health Center Prof. Dr. Ivan Temkov - Burgas EOOD, Burgas, Bulgaria|State Psychiatry Hospital - Kardzhali, Kardzhali, Bulgaria|State Psychiatry Hospital Sv. Ivan Rilski, Novi Iskar, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria|Mental Health Center - Ruse EOOD, Ruse, Bulgaria|University Multiprofile Hospital for Active Treatment Alexandrovska EAD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment - Targovishte AD, Targovishte, Bulgaria|Mental Health Center - Veliko Tarnovo EOOD, Veliko Tarnovo, Bulgaria|Mental Health Center - Vratsa EOOD, Vratsa, Bulgaria|Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej im. Dr. Stanislawa Deresza w Choroszczy, Choroszcz, Poland|Uniwersyteckie Centrum Kliniczne w Gdansku Klinika Psychiatrii Doroslych, Gdańsk, Poland|NZOZ Centrum Medyczne HCP Sp. z o. o., Poznań, Poland|NZOZ Prywatna Klinika Psychiatryczna Inventiva, Tuszyn, Poland|Clinic for Psychiatric Disorders Dr Laza Lazarevic, Belgrade, Serbia|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Center Dr Dragisa Misovic-Dedinje, Belgrade, Serbia|Special Hospital for Psychiatric Diseases Kovin, Kovin, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center of Vojvodina, Novi Sad, Serbia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03259555/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03259555/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03259555"
